logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10246457 B1

PDFFull Text
Date of Patent:
Apr. 02, 2019

Filed:

Apr. 04, 2016

Indazole and azaindazole btk inhibitors

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Tony Siu, Brookline, MA (US);

Michael D. Altman, Needham, MA (US);

Brian M. Andresen, Sharon, MA (US);

Jian Liu, Edison, NJ (US);

Joseph Kozlowski, Princeton, NJ (US);

Sobhana Babu Boga, Scotch Plains, NJ (US);

Younong Yu, East Brunswick, NJ (US);

Rajan Anand, Fanwood, NJ (US);

Jiaqiang Cai, Shanghai, CN;

Dahai Wang, Shanghai, CN;

Shilan Liu, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Matthew A. Leff

Laura M. Ginkel

Primary Examiner:

D Margaret M Seaman

Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 401/10 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); A61P 19/02 (2006.01); A61K 45/06 (2006.01); C07D 231/56 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01); C07D 231/56 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/10 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01);
Abstract

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X, X, R, R, Rand Rare as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Find Patent Forward Citations

Loading…